Variability Assessment of 90 Salivary Proteins in Intraday and Interday Samples from Healthy Donors by Multiple Reaction Monitoring‐Mass Spectrometry

Hsiao, Yung-Chin; Chu, Lichieh Julie; Chen, Yi-Ting; Chi, Lang‐Ming; Chien, Kun-Yi; Chiang, Wei‐Fan; Chang, Ya-Ting; Chen, Szu-Fan; Wang, Wei-Shun; Chuang, Yao-Ning; Lin, Shinn-Yn; Chien, Chih‐Yen; Chang, Kai‐Ping; Chang, Yu‐Sun; Yu, Jau‐Song

doi:10.1002/prca.201700039

Cited by 21 publications

(10 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With its characteristics of late diagnosis, high mortality rates, and morbidity, oral cancer, among the more prevalent cancers worldwide, represents a global public health problem. Based on the presumption that early diagnosis and timely therapy can prolong patient survival, our team has worked for years on the development of biomarkers for early diagnosis and prognostic assessment of oral cancer patients [ 37 , 55 , 57 , 58 , 59 , 60 ]. Accumulating evidence from different groups suggests that salivary levels of MMPs, including MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-12, and MMP-13, have potential as diagnostic markers of OSCC [ 52 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 ].…”

Section: Discussionmentioning

confidence: 99%

Verification of Saliva Matrix Metalloproteinase-1 as a Strong Diagnostic Marker of Oral Cavity Cancer

Chang

Chu

Liu

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

Oral squamous cell carcinoma (OSCC) accounts for >90% of cases of oral cancer, including cancer at the lip and oral cavity and cancer at the oropharynx. Most OSCCs develop from oral potentially malignant disorders (OPMDs), which consist of heterogeneous lesions with different malignant transformation potentials that make early detection of OSCC a challenge. Using a targeted mass spectrometry-based assay to compare multiple candidate proteins, we previously identified matrix metalloproteinase-1 (MMP-1) as one of the most promising salivary OSCC biomarkers. To explore the clinical utility of MMP-1 in OSCC detection, we developed an in-house, sensitive enzyme-linked immunosorbent assay (ELISA) for measuring MMP-1 content, and tested it on saliva samples from 1160 subjects (313 healthy controls, and 578 OPMD and 269 OSCC patients) collected at two medical centers. Salivary MMP-1 levels measured by our in-house ELISA significantly discriminated OSCC patients from non-cancerous groups. A receiver operating characteristic curve analysis showed that MMP-1 was effective in separating non-cancer groups from patients with OSCCs at the oral cavity. Additionally, salivary MMP-1 levels in oral cavity cancer patients were highly correlated with tumor progression (tumor size, lymph node metastasis, and overall stage). Collectively, our results indicate that salivary MMP-1 is an effective biomarker for OSCC that can be sensitively detected using our newly developed ELISA. The newly developed MMP-1 ELISA may be used as a new adjunctive tool to aid in detecting and monitoring OSCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Verification of Saliva Matrix Metalloproteinase-1 as a Strong Diagnostic Marker of Oral Cavity Cancer

Chang

Chu

Liu

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…MMP1-derived peptides, the most favorable biomarker, was then developed for dried saliva spot samples through immuno-MALDI and LC-MRM-MS for the purpose of rapid screening in the future (Hsiao et al, 2020). A total of 99 disease-associated proteins were precisely quantified through LC-MRM MS for assessing the intraindividual and interindividual variability in the saliva of healthy donors, thus facilitating the future development of an oral screening assay (Hsiao et al, 2018). The abundance of these disease-associated proteins in healthy populations is shown in Figure . 3C.…”

Section: Clinical Applications Of the Targeted Quantitation Of Saliva...mentioning

confidence: 99%

Targeted protein quantitation in human body fluids by mass spectrometry

Chen

Liao

Wang

et al. 2022

Mass Spectrometry Reviews

View full text Add to dashboard Cite

Human body fluids (biofluids) contain various proteins, some of which reflect individuals' physiological conditions or predict diseases. Therefore, the analysis of biofluids can provide substantial information on novel biomarkers for clinical diagnosis and prognosis. In the past decades, mass spectrometry (MS)‐based technologies have been developed as proteomic strategies not only for the identification of protein biomarkers but also for biomarker verification/validation in body fluids for clinical applications. The main advantage of targeted MS‐based methodologies is the accurate and specific simultaneous quantitation of multiple biomarkers with high sensitivity. Here, we review MS‐based methodologies that are currently used for the targeted quantitation of protein components in human body fluids, especially in plasma, urine, cerebrospinal fluid, and saliva. In addition, the currently used MS‐based methodologies are summarized with a specific focus on applicable clinical sample types, MS configurations, and acquisition modes.

show abstract

“…While CSF can be problematic to acquire, more peripheral biofluids, such as serum, urine, and saliva, can and are easily acquired from pediatric patients in ambulatory settings every day. In this sense, they are far more practical sources for pediatric brain tumor biomarker discovery than CSF; but discoveries in these media must be approached cautiously, as biomarkers in these biofluids are subject to dilution and filtration at multiple points between synthesis and their collection sites, sometimes greatly compromising the fidelity of the observed biomarker concentration [67][68][69] .…”

Section: Serum Biomarkersmentioning

confidence: 99%

Peripheral biomarkers for pediatric brain tumors: current advancements and future challenges

Bookland¹,

Kolmakova²

2019

JCMT

View full text Add to dashboard Cite

Circulating biomarkers-nucleic acids, proteins, and metabolites-have been used in several adult oncologic processes to affect early detection, measure response to treatment, and offer prognostic information. The identification and validation of biomarkers for pediatric brain tumors, however, has been meager by comparison. Early detection and serial screening of pediatric brain tumors has the potential to improve outcomes by allowing for rapid therapeutic interventions and more targeted therapies. This is particular resonant for pediatric brain tumors where treatment success is heavily dependent on early surgical intervention. This highlights the need for biomarker development in pediatric neuro-oncology. The authors reviewed current circulating biomarker targets in various biofluid reservoirs and discuss the current barriers to biomarker development in pediatric neuro-oncology patients.

show abstract

Variability Assessment of 90 Salivary Proteins in Intraday and Interday Samples from Healthy Donors by Multiple Reaction Monitoring‐Mass Spectrometry

Abstract: Our study elucidated the intra- and interindividual variability of 90 disease-related proteins in saliva samples from healthy donors. The findings may facilitate the further development of salivary biomarkers for oral and systemic diseases.

Cited by 21 publications

References 52 publications

Verification of Saliva Matrix Metalloproteinase-1 as a Strong Diagnostic Marker of Oral Cavity Cancer

Verification of Saliva Matrix Metalloproteinase-1 as a Strong Diagnostic Marker of Oral Cavity Cancer

Targeted protein quantitation in human body fluids by mass spectrometry

Peripheral biomarkers for pediatric brain tumors: current advancements and future challenges

Contact Info

Product

Resources

About